Mylan: Seeing is Believing

menu

Press Releases

Jun 24, 2004

Mylan Receives FDA Approval for Levothyroxine Sodium Tablets
Jun 23, 2004

Mylan Sues FDA for Injunction Against Fentanyl Ruling
Jun 22, 2004

Mylan Laboratories Appoints Michael Marquard President of Mylan Bertek Pharmaceuticals
Jun 17, 2004

Mylan Declares Quarterly Cash Dividend
Jun 15, 2004

Mylan Announces Name Change for its Branded Products Subsidiary to Mylan Bertek
Jun 10, 2004

Mylan Receives FDA Approval for Ciprofloxacin Tablets
May 11, 2004

Mylan Reports Record EPS, Revenues and Net Earnings for Fiscal 2004

Annual Financial Highlights: * Record diluted earnings per share of $1.21 compared to $0.96 in the prior fiscal year. * Net revenues increased 8% to a record $1.37 billion. * Net earnings increased 23% to a record $334.6 million.
May 6, 2004

Mylan Receives Tentative Approval for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets
May 5, 2004

Mylan Submits New Drug Application for Nebivolol
Apr 29, 2004

Mylan Announces Earnings Release Date and Conference Call Information for Fourth Quarter and Fiscal 2004

Show per page

Company

Products

Update on Meridian’s Voluntary Worldwide Recall of EpiPen® Auto-Injector

News

Investors

Global Social Responsibility

Community Health

Careers

Resources and information to help prescribe, dispense and take medicine with confidence.

Pharmacists

Educational materials to help empower your customers.
Patients

What to know about our high quality generics.
Physicians

Details about our brand name and generic medicines.
Institutional Customers

Resources that meet the specific needs of your institution.

Explore

California Supply Chains Act

Copyright © 2019 Mylan N.V. All Rights Reserved.

For U.S. Audiences Only